Financial Performance - In 2021, the company's operating revenue reached ¥1,999,916,888.19, representing a 46.29% increase compared to ¥1,367,087,241.13 in 2020[17] - The net profit attributable to shareholders was ¥323,754,754.88, a 35.62% increase from ¥238,729,340.15 in the previous year[17] - The net profit after deducting non-recurring gains and losses was ¥307,864,117.27, up 30.04% from ¥236,753,234.90 in 2020[17] - The net cash flow from operating activities was ¥508,839,385.25, a significant increase of 191.63% compared to ¥174,479,180.11 in 2020[17] - As of the end of 2021, the total assets amounted to ¥4,895,377,815.83, reflecting an 11.10% increase from ¥4,406,335,461.47 at the end of 2020[17] - The net assets attributable to shareholders increased to ¥2,174,978,008.51, a 19.27% rise from ¥1,823,503,185.33 in 2020[17] - The basic and diluted earnings per share increased by 32% to 1.32 RMB per share[18] - The weighted average return on equity decreased by 1.67 percentage points to 16.04%[18] Dividend and Shareholder Information - The company plans to distribute a cash dividend of ¥5 per 10 shares and to increase capital by 4 shares for every 10 shares held[4] - The total number of shares held by the chairman, Hu Jinsheng, remained unchanged at 50,274,000 shares, with a pre-tax compensation of 1.28 million CNY for the reporting period[109] - The total number of shares held by the general manager, Hu Jian, also remained unchanged at 44,100,000 shares, with a pre-tax compensation of 1.18 million CNY[109] - The total pre-tax compensation for all directors and supervisors amounted to 6.09 million CNY for the reporting period[111] - The company proposed a cash dividend of 5 yuan per 10 shares (including tax) for the 2021 fiscal year, pending approval at the annual shareholders' meeting[136] Research and Development - The company successfully participated in the national centralized procurement, winning bids for its Iohexol and Iopamidol injection products[29] - The company submitted supplementary materials for iodinated contrast agents and registered an application for gadobutrol injection in December 2021, continuing its R&D efforts in the contrast agent field[30] - A total of 69 patents have been granted or are under review, including 49 invention patents, indicating a strong focus on innovation[31] - The company’s R&D expenses increased by 41.82% to CNY 124,580,729.29, reflecting a commitment to innovation[43] - The company has established five R&D centers and has over 30 authorized invention patents, showcasing its strong R&D capabilities[40] - The company aims to enhance its R&D capabilities and expand its product lines, focusing on X-ray contrast agents and other imaging agents[96] Market and Sales Strategy - The company has established long-term partnerships with major pharmaceutical companies in China, enhancing its market presence and distribution capabilities[36] - The sales model includes direct sales for domestic markets and self-export or distributor sales for international markets, ensuring a stable supply chain[36] - The company aims to become the largest and most comprehensive manufacturer of contrast agents globally, focusing on filling domestic gaps[38] - The company intends to leverage national procurement selections to establish a comprehensive sales network across provinces in China[99] - The company will actively explore international markets, particularly in Europe, Japan, Southeast Asia, the Middle East, and South America[99] Environmental Compliance and Management - The company has established a hazardous waste storage facility with a maximum capacity of 650 tons, compliant with environmental protection standards[150] - The company has implemented an annual self-monitoring plan, with key pollutants monitored every two hours for COD, pH, ammonia nitrogen, and total nitrogen[162] - The company has committed to enhancing its environmental management practices and awareness following the administrative penalty[157] - The company operates a RTO incineration system with a processing capacity of 15,000 standard cubic meters per hour, ensuring effective waste gas treatment[161] - The company has established a comprehensive environmental risk emergency response mechanism to ensure effective handling of environmental incidents[162] Governance and Compliance - The company has received a standard unqualified audit report from Tianjian Accounting Firm[5] - The board of directors has ensured the authenticity and completeness of the annual report, with no false records or misleading statements[5] - The company has not faced any penalties from securities regulatory authorities in the past three years[119] - The company has not reported any objections raised by directors regarding company matters[123] - The company has implemented a performance assessment system to determine actual remuneration for directors and senior management[116] Financial Management and Investments - The company has approved the use of up to 300 million RMB of idle raised funds for cash management, ensuring the safety and liquidity of investments[190] - The company has engaged in bank wealth management with a total amount of 80 million RMB from idle raised funds, with no overdue amounts[189] - The total guarantee amount (including guarantees to subsidiaries) is 685,516,361.36 RMB, accounting for 31.52% of the company's net assets[187] - The company has made structured deposits with China Bank and Citic Bank, with annualized returns ranging from 1.50% to 4.91%[191] - The company has not disclosed any significant related party transactions or guarantees during the reporting period[186] Social Responsibility - The company donated 15 million yuan during the fourth Taizhou Charity Conference, ranking second in the city for charitable contributions[167] - Over the past three years, the company has donated a total of 7.87 million yuan to various charitable organizations and social causes[167] - The company has implemented a stock incentive plan to attract and retain talented employees, enhancing their motivation and creativity[166]
司太立(603520) - 2021 Q4 - 年度财报